Contraindications

• Hypersensitivity to drug• Pregnancy or breastfeeding

Precautions

Use cautiously in:• elderly patients• females of childbearing age.

Administration

☞ Give by central or peripheral I.V. route only.• Reconstitute by adding 5 ml of sterile water for injection to vial for bolus injection, or dilute with normal saline solution or dextrose 5% in water to a volume of 50 ml and infuse over 20 to 30 minutes. Discard any remaining product after preparing each dose.• Don't infuse other drugs simultaneously through same I.V. line.• Know that drug should be used only as part of regimen that includes cyclosporine and corticosteroids.

Patient teaching

• Teach patient about purpose of therapy. Explain that drug decreases the risk of acute organ rejection.• Tell patient he may be more susceptible to infection because of drug's immunosuppressant effect.• Inform patient that he'll need lifelong immunosuppressant drug therapy.• Advise women of childbearing age to use reliable contraception before, during, and for 2 months after therapy.• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

Administration

• Use spacer device to ensure proper delivery of dose and to help prevent candidiasis and hoarseness.• After inhalation, tell patient to hold his breath for a few seconds before exhaling.• For greater efficacy, wait 1 minute between inhalations.• If patient is also receiving a bronchodilator, administer it at least 15 minutes before beclomethasone.• Discontinue drug after 3 weeks if symptoms don't improve markedly.

Interactions

Patient monitoring

Patient teaching

• Instruct patient to hold inhaled drug in airway for several seconds before exhaling and to wait 1 minute between inhalations.• Advise patient to rinse mouth after using inhaler and to wash and dry inhaler thoroughly to help prevent fungal infections and sore throat.• Encourage patient to document use of drug and his response in a diary.• If patient is also using a bronchodilator, teach him to use it at least 15 minutes before beclomethasone.• As appropriate, review all other significant and life-threatening adverse reactions.

basiliximab

/bas·i·lix·i·mab/ (bas″ĭ-lik´sĭ-mab) a chimeric monoclonal antibody that is an interleukin-2 receptor antagonist; used in the prophylaxis of acute organ rejection after renal transplantation.

basiliximab

a monoclonal antibody used for immunosuppression.

indications This drug is used in combination with cyclosporine and corticosteroids to treat acute allograft rejection in renal transplant patients.

contraindications Known hypersensitivity to this drug contraindicates its use.

basiliximab

A high-affinity, mouse–human chimeric monoclonal antibody raised against the alpha chain (CD25) of the IL-2 receptor on T cells. It is used to prevent or minimise the rejection of transplanted solid organs, and meant to complement other drugs.

basiliximab

basiliximab

A chimeric monoclonal antibody to the alpha chain (CD 25), one of the three transmembrane protein chain receptors of INTERLEUKIN 2R. This interleukin plays an important role in T lymphocyte proliferation. On resting T cells the level of expression of CD 25 is low but allogenic stimulation after organ grafting causes it to rise. This provides specificity for a means of control of graft rejection. Trials have suggested that basiliximab can reduce graft rejection by one third. A brand name is Simulect.

This US FDA approval was based on the company's two randomised multicentre studies comparing Thymoglobulin to interleukin-2 receptor antagonists (IL2RA: basiliximab or daclizumab) in deceased donor kidney transplant recipients.

After the transplant, the patient received basiliximab, methylprednisolone and byclosporine for induction immune suppression and then triple therapy with cyclosporine, prednisone and myclophenolate mofetil (MMF) for maintenance immune suppression.

Also, in a single case study of severe erosive OLP, the use of the anti IL-2 receptor agent basiliximab (Bolus intravenous infusion of 20 mg, 2 doses, 4 days apart) resulted in remission of oral lesions, which was only temporal as lesions reappeared soon after the agent was withdrawn.

All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.